Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome
This case series examines treatment with anti–programmed cell death 1 (PD1) immunotherapy for patients with basal cell nevus syndrome.
Related Articles
Building Trust in AI for Scientific Research
This Medical News article is an interview with National Academy of Sciences President Marcia McNutt, PhD, and JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD,…
Large Language Model Responses to Adolescent Patient and Proxy Messages
This cross-sectional study assesses a language model’s ability to discern between messages from adolescent patients and those from their parents/guardians and subsequently generate appropriate responses.
The Microbiome
Dermatology and our patients have benefited greatly from scientific advances over the past decades.
Primary Care Practice Telehealth Use and Low-Value Care Services
This cohort study evaluates whether the practice-level use of telehealth is associated with delivery of low-value care in primary care practices in Michigan.
Racial Disparities in Genetic Detection Rates for Inherited Retinal Diseases
This study investigates the genetic detection rates of wide-panel testing in Black and non-Hispanic White patients with IRDs.
Racial and Ethnic Disparities in Fentanyl and Polysubstance Overdose Deaths
This cross-sectional study describes US overdose death patterns for fentanyl and fentanyl combined with opioids, heroin, cocaine, methamphetamine, or benzodiazepines by race and ethnicity from…
Long-Term Adverse Effects and Complications After Prostate Cancer Treatment
This cohort study assesses the long-term adverse effects and complications of prostate cancer treatment in treated patients compared with a general population of older males.
Heat Waves and Adverse Health Events Among Dually Eligible Individuals 65 Years and Older
This time-series study assesses the association between heat waves and adverse health events among dually eligible individuals 65 years and older.
Pharmacokinetic Modeling of Spesolimab Reveals Key Differences Between IV and Subcutaneous Dosing for Generalized Pustular Psoriasis
A poster presented at the 2024 Elevate-Derm West Conference outlines the pharmacokinetic profiles of spesolimab via intravenous and subcutaneous administration.
Day 1 Recap: Elevate-Derm West 2024
Catch up on coverage from the first day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.